Mounjaro is a diabetes injection; Contrave is a weight loss pill. Mounjaro (tirzepatide) suppresses appetite through dual GIP/GLP-1 hormonal signaling. Contrave (naltrexone/bupropion) reduces food cravings through the brain’s reward pathways. For weight loss patients, the appropriate tirzepatide product is Zepbound, not Mounjaro.
The key difference
Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes. It produces substantial weight loss as a secondary effect through hormonal appetite suppression and improved metabolic signaling. Its weight loss counterpart is Zepbound.
Contrave (naltrexone/bupropion) is FDA-approved for chronic weight management. It targets the brain’s reward circuitry — naltrexone blocks the opioid pathways that make food feel rewarding, while bupropion suppresses appetite and has antidepressant properties.
Mounjaro reduces how much you want to eat. Contrave reduces how rewarding eating feels. They address fundamentally different drivers of weight gain.
Side-by-side comparison
| Feature | Mounjaro | Contrave |
|---|---|---|
| Active ingredient | Tirzepatide | Naltrexone/bupropion |
| Mechanism | Dual GIP/GLP-1 agonist | Opioid antagonist + NDRI |
| FDA indication | Type 2 diabetes | Chronic weight management |
| Administration | Weekly injection | Oral tablet, twice daily |
| Avg weight loss | ~15–25 lbs (secondary endpoint) | approximately 5–6% body weight |
| Best for | Maximum appetite suppression + metabolic improvement | Cravings-driven and emotional eating |
| Side effects | Nausea, diarrhea, decreased appetite | Nausea, headache, insomnia, constipation |
| Insurance for weight loss | Not covered (off-label) | Good; generic available |
| Cost without insurance | ~high out-of-pocket pricing | moderate out-of-pocket pricing |
| Weight-loss version | Zepbound | Already approved for weight loss |
Choosing between them
- Cravings and reward-seeking drive your eating
- You prefer pills over injections
- You have concurrent depression
- Budget is a primary concern
- Insurance requires step therapy before GLP-1
- Maximum weight loss is the priority
- You want dual-hormone metabolic benefits
- You have obstructive sleep apnea
- Your insurance covers GLP-1 weight loss drugs
- You’re comfortable with weekly injections
If you’re comparing Mounjaro and Contrave for weight loss, the more appropriate comparison is Contrave vs. Zepbound. Mounjaro is a diabetes medication. Zepbound is the same tirzepatide molecule approved for weight management, with proper insurance pathways and clinical monitoring.
Why this comparison misses the mark
Patients searching for "Mounjaro vs Contrave" are usually trying to decide between an injectable and an oral medication for weight loss. But Mounjaro is not FDA-approved for weight loss — Zepbound is. Both contain tirzepatide, but Zepbound was studied specifically in weight management trials (SURMOUNT-1 through SURMOUNT-5) and carries the FDA indication for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
The more useful comparison is Contrave vs. Wegovy (which also covers GLP-1 vs. oral medication trade-offs). These medications work through completely different mechanisms. Contrave combines naltrexone and bupropion to reduce food cravings and the reward response to eating. Zepbound activates both GIP and GLP-1 receptors to reduce appetite, slow gastric emptying, and improve insulin sensitivity. In clinical trials, tirzepatide produced significantly greater weight loss — up to 22.5% of body weight in SURMOUNT-1 — while Contrave typically produces 5–8% weight loss.
The trade-off is route of administration, cost, and insurance coverage. Contrave is an oral pill taken twice daily. Zepbound is a once-weekly injection. At PEAK, we help patients weigh these factors during their initial consultation.
How we help you choose
PEAK prescribes both Contrave and Zepbound (not Mounjaro) for weight management. The right choice depends on what drives your eating and your overall health profile.
For patients whose overeating is driven by cravings and reward-seeking, Contrave’s mechanism directly targets the problem. For patients seeking maximum weight reduction, Zepbound offers the strongest clinical evidence. Your clinician will help match the medication to the cause. Schedule a consultation.
Boxed warning — Contrave (naltrexone/bupropion): Contrave carries an FDA boxed warning for suicidal thoughts and behaviors associated with the bupropion component. Patients should be monitored for neuropsychiatric symptoms, especially during early treatment. Contrave also increases seizure risk and should not be used with excessive alcohol consumption or abrupt discontinuation of alcohol, benzodiazepines, or antiepileptics.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
